Autonomic Inodilator Mechanisms era
Sir James Whyte Black, a central figure of the era, demonstrated that beta-adrenergic blockade with propranolol could blunt sympathetic chronotropy and inotropy, clarifying autonomic contributions to heart rate, contractility, and hemodynamics. Eugene Braunwald synthesized mechanistic and translational pharmacology, performing human hemodynamic studies and guiding how inotropes and vasodilators alter cardiac output versus vascular resistance in angina and heart failure. Robert Lefkowitz and colleagues advanced receptor pharmacology during this period by delineating beta-adrenergic receptor signaling and desensitization via G protein coupling, providing a molecular basis for dose–response and myocardial energetics. Together with parallel in vivo dose–response work in animal models and pharmacologic provocations, these authors helped establish benchmarks for clinical pharmacology and early translational therapy balancing heart performance and vascular tone.
Receptor-Endothelium Integration era
Robert Furchgott's work in the 1980s established the endothelium-derived relaxing factor as a central mediator of vascular tone, reframing receptor pharmacology in terms of endothelial NO signaling. Louis Ignarro then clarified NO as the endothelium-derived relaxing factor and mapped the NO–cGMP signaling cascade that translates receptor-mediated vasodilator stimuli into vascular responses. Ferid Murad demonstrated NO’s function as a signaling molecule through soluble guanylyl cyclase, providing a unifying biochemical mechanism linking receptor pharmacology to endothelial control of vasomotion. Scholars such as Paul Insel articulated the receptor–endothelium axis and showed how disease-modified NO bioavailability and receptor signaling shape therapeutic efficacy, safety, and remodeling after myocardial injury.